ReCode Therapeutics Appoints Dean J. Mitchell as Board Chairman

ReCode Therapeutics, a company at the forefront of genetic medicine, has recently announced the appointment of Dean J. Mitchell as the chairman of its Board of Directors. This strategic move introduces an industry veteran with over 30 years of experience in biotechnology and pharmaceuticals to ReCode's leadership team.

Dean J. Mitchell brings a wealth of knowledge and a proven track record in steering biopharma companies towards significant growth. His extensive career includes roles as a board director and corporate executive, making his addition to ReCode’s board a significant milestone for the company. Shehnaaz Suliman, M.D., MBA, M.Phil., CEO of ReCode Therapeutics, expressed her enthusiasm about the appointment, highlighting Mitchell’s expertise in expanding and scaling companies in the biopharma sector. Suliman noted that Mitchell's experience would be instrumental in supporting ReCode's ongoing and future growth, particularly as the company advances its respiratory clinical development programs and expands its portfolio using the SORT LNP delivery platform.

Dean J. Mitchell shared his eagerness to join ReCode at a crucial point in its journey. He emphasized the company's recent achievements in its lead clinical programs and its ongoing efforts in gene correction research. Mitchell expressed his commitment to collaborating with the board and executive team to develop novel therapies aimed at providing essential treatments for patients with rare diseases.

Currently, Dean J. Mitchell serves as the chairman of the Board of Directors of Praxis Precision Medicines, Inc., a position he has held since 2020. He also holds directorship roles at Theravance Biopharma, Inc. (since 2014) and Precigen (since 2009). His past roles include chairman of the board at Kinnate Biopharma, Inc. and ImmunoGen, Inc., both of which were sold in 2024, as well as executive board chairman at Covis Pharma Holdings until its sale in 2020, and board chairman at PaxVax Corporation until its sale in 2018.

Mitchell's executive experience is extensive, having previously served as president and CEO of Lux Biosciences, Inc., which focuses on ophthalmic disease treatments. He also held leadership positions at Alpharma, Inc., a specialty pharmaceutical company, and Guilford Pharmaceuticals, Inc., a company specializing in oncology and acute care, both of which were acquired by larger pharmaceutical entities. Additionally, Mitchell has held executive roles at industry giants Bristol Myers Squibb and GlaxoSmithKline. He holds a B.A. from City University London and a B.Sc. in biology from Coventry University.

ReCode Therapeutics is a clinical-stage genetic medicines company renowned for its precision delivery technologies that are set to revolutionize mRNA and gene correction therapeutics. The company's proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform facilitates highly precise delivery of genetic medicines to specific organs, tissues, and cells, enhancing the efficacy and potency of treatments. ReCode’s leading programs include RCT1100, aimed at treating primary ciliary dyskinesia caused by DNAI1 gene mutations, and RCT2100, targeting the 10-13% of cystic fibrosis patients with Class I CFTR gene mutations unresponsive to current therapies. These inhaled, disease-modifying mRNA-based therapies are formulated using the SORT LNP delivery platform.

ReCode Therapeutics is also broadening its pipeline to address a spectrum of genetic diseases, including those affecting the musculoskeletal system, central nervous system, liver, and infectious diseases. The company has been recognized by the San Francisco Business Times and Silicon Valley Business Journal as a top workplace, reflecting its commitment to innovation and excellence in the biopharma field.